Nature Communications (Sep 2021)
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
- Michael S. Hwang,
- Michelle S. Miller,
- Puchong Thirawatananond,
- Jacqueline Douglass,
- Katharine M. Wright,
- Emily Han-Chung Hsiue,
- Brian J. Mog,
- Tihitina Y. Aytenfisu,
- Michael B. Murphy,
- P. Aitana Azurmendi,
- Andrew D. Skora,
- Alexander H. Pearlman,
- Suman Paul,
- Sarah R. DiNapoli,
- Maximilian F. Konig,
- Chetan Bettegowda,
- Drew M. Pardoll,
- Nickolas Papadopoulos,
- Kenneth W. Kinzler,
- Bert Vogelstein,
- Shibin Zhou,
- Sandra B. Gabelli
Affiliations
- Michael S. Hwang
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Michelle S. Miller
- Howard Hughes Medical Institute
- Puchong Thirawatananond
- Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine
- Jacqueline Douglass
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Katharine M. Wright
- Howard Hughes Medical Institute
- Emily Han-Chung Hsiue
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Brian J. Mog
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Tihitina Y. Aytenfisu
- Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine
- Michael B. Murphy
- Cytiva
- P. Aitana Azurmendi
- Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine
- Andrew D. Skora
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Alexander H. Pearlman
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Suman Paul
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Sarah R. DiNapoli
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Maximilian F. Konig
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Chetan Bettegowda
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Drew M. Pardoll
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center
- Nickolas Papadopoulos
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Kenneth W. Kinzler
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Bert Vogelstein
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Shibin Zhou
- Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Sandra B. Gabelli
- Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-25605-4
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Chimeric antigen receptor T cells in the clinic currently target cell-type-specific extracellular antigens on malignant cells. Here, authors engineer tumor-specific chimeric antigen receptor T cells that target human leukocyte antigen-presented neoantigens derived from mutant intracellular proteins.
